Oncolytics Biotech Inc.
NASDAQ:ONCYBiotechnology
+$0.03 today
- Market cap
- $50.41M
- Beta
- 1.08
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.32
Volume 0.38M
Average 1.26M
ONCY Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Oncolytics Biotech Inc.NASDAQ: ONCY
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of CA$6.35M rose 55.5% year over year, ahead of the +4.7% change in trailing-twelve-month research & development. Sequentially, it rose 114.3% from the prior quarter. Over 3 fiscal years it compounded at +15.5% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +55.5% holds above the trailing-twelve-month pace of +4.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
CAD · from the income statement
- Latest · FY2025
- 18.27M CAD
- Year-over-year change
- -15.6%
- 4-year CAGR
- +15.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.27M | -15.6% |
| FY2024 | 2024-12-31 | 21.65M | +65.0% |
| FY2023 | 2023-12-31 | 13.12M | +10.7% |
| FY2022 | 2022-12-31 | 11.85M | +15.0% |
| FY2021 | 2021-12-31 | 10.31M | — |
Research & Development vs competitors
How ONCY compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +4.7% is the 6th highest of 9, against a peer median of +73.5%.
- Over three fiscal years its annual growth of +15.5% compares with a peer median of -9.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.68B USD | +26273.1% | +50.2% | 46313.4% | |
| LTM Mar 2026 | $135.36M USD | -19.9% | -12.2% | 86.2% | |
| LTM Mar 2026 | $108.76M USD | -25.2% | -14.7% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $99.41M USD | +115.1% | +40.7% | — |
| LTM Mar 2026 | $32.14M USD | +45.7% | -7.4% | 428.8% | |
| LTM Mar 2026 | $20.26M USD | +102.3% | +57.1% | — | |
| LTM Mar 2026 | $20.04M USD | +101.3% | -58.6% | — | |
| LTM Mar 2026 | CA$19.63M CAD | +4.7% | +15.5% | — | |
| LTM Mar 2026 | $12.86M USD | -17.9% | -24.0% | 9596.3% | |
| Peer median (excluding ONCY) | — | +73.5% | -9.8% | 5012.5% | |
Competitors are the stored peer set for ONCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 360.58K | 301.11K | 298.59K | 87K | 70K |
| Gross Profit | (360.58K) | (301.11K) | (298.59K) | (87K) | (70K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 10.31M | 11.85M | 13.12M | 21.65M | 18.27M |
| Selling, General & Admin | 10.26M | 8.53M | 11.62M | 13.34M | 21.15M |
| Operating Expenses | 20.56M | 20.38M | 24.74M | 34.98M | 39.41M |
| Depreciation & Amortization | 360.58K | 301.11K | 298.59K | 102K | 96.05K |
| EBITDA | (20.58M) | (18.71M) | (20.19M) | (34.88M) | (39.41M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (20.93M) | (20.68M) | (25.04M) | (34.98M) | (39.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 99K | 528K | 1.33M | 1.2M | 529.64K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (15.88K) | 1.67M | 4.55M | 3.4M | 61.75K |
| Income Before Tax | (20.94M) | (19.01M) | (20.49M) | (31.58M) | (39.35M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 39.42K | 64.52K | 71.87K | 130K | 108.4K |
| Net Income | (20.98M) | (19.08M) | (20.56M) | (31.71M) | (39.46M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.49) | (0.44) | (0.41) | (0.41) | (0.41) |
| EPS (Diluted) | (0.49) | (0.44) | (0.41) | (0.41) | (0.41) |
| Weighted Avg Shares | 53.51M | 58.03M | 67.62M | 76.48M | 95.86M |
| Weighted Avg Shares (Diluted) | 53.51M | 58.03M | 67.62M | 76.48M | 95.86M |
Oncolytics Biotech Inc.
NASDAQ:ONCY
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.